Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 341

Three leading Aussie stocks dependent on China

The signing of the phase one agreement by US President Donald Trump and Chinese Vice Premier Liu marks a thaw in the 18-month row between the world's two largest economies.

But scepticism remains because the deal doesn't fully eliminate the tariffs that have slowed the global economy. It also sets hard-to-achieve purchase targets.

Companies dependent on China

Looking some of the large Australian companies with the greatest China exposure – outside of mining conglomerates – three companies stand out. Each of these companies count sales into China as a considerable driver of revenue.

At the height of the trade tensions last year, Morningstar Australia's Director of Equity Research Adam Fleck didn't anticipate any long-term negative effects.

He conceded that any company deriving a lot of money from Chinese consumers was likely to be hurt by a slowdown in China's economy.

Conversely, Fleck said that if tariffs applied to goods from the US it would be good news for Australian companies.

China’s economy is expected to have grown 6% in October-December from a year earlier, according to analysts polled by Reuters, unchanged from the previous quarter’s pace, which was the slowest since 1992 - the earliest quarterly data on record.

Let's take a brief look at the three companies.

1. Treasury’s China sales on track

Treasury Wine Estates, a global wine company that increasingly targets high-end consumers, benefited from a drop in the tariffs China imposed on Australian winemakers in the first half of 2019 – at the same time as US wine exports to the country fell sharply.

Fleck sees continued growth in Treasury's Asian business, which comprises 26% of sales and 31% of operating income. This is largely because of the company's "premiumisation" drive in boosting its high-end brands and reducing sales of lower-end wine.

His outlook for double-digit average annual volume gains in Treasury's sales in China remains on track, forecasting 14% annual volume growth over the next several years.

"Chinese wine consumption has climbed off a low base, averaging 16% annual volume gains since 2011, as the region’s climbing consumer wealth has driven demand for upmarket brands," says Fleck.

He expects volume gains will remain "tough to come by" but believes Treasury's focus on the premium end of the market and continued growth in China and other Asian countries positions it favourably.

Treasury Wine's fair value estimate of $12.80 was lifted from $12.30 in August, on an expectation of higher margins over the long term.

But Fleck also sounds a note of caution, given the company currently trades at $17.24, some 35% above what Morningstar thinks it is worth.

2. A2 Milk's premium pricing

New Zealand-based milk and infant formula company A2 Milk has long been linked with Chinese consumers, especially in connection with professional "daigou" shoppers who legally buy the milk powder to sell overseas.

But Fleck viewed A2 as largely immune to fallout from the trade tariffs, even while highlighting sales of infant formula into China as the company's key medium-term growth avenue.

"We forecast rising prices, new products, and a continued consumer shift toward foreign brands to drive higher revenue per volume, and high-single-digit growth for overall value in the market," Fleck said in late 2019.

"We see A2 increasing revenue in this geography at a 16% annual clip through fiscal 2029, with Chinese infant formula climbing to about 90% of the company’s consolidated earnings before interest, tax, depreciation and amortisation."

He notes that A2's premium pricing gives it an advantage over other dairy producers, which has seen its operating margins top 30% from less than 1% in fiscal 2015.

"We see a ceiling to A2's profitability upside but the company's business strategy supports sky-high returns on invested capital," Fleck says.

He believes ROIC will average more than 230% over the next five years. This, combined with a debt-free balance sheet and strong free cash flow, underpins the narrow moat of competitive advantage attributed to A2 Milk.

The company's fair value estimate of $14.50 as of August last year was lifted from $13.60, on the back of solid financial results for fiscal 2019. A2 shares closed at $14.23 on Thursday and are considered fairly valued.

3. Blackmores hits some regulations

Vitamin maker Blackmores, which relies on Asia for around 40% of total group revenue, is also trading in line with Morningstar's fair value estimate.

Equity analyst Nicolette Quinn highlights China as a large opportunity for narrow-moat Blackmores, anticipating around 10% annual growth in the market from fiscal 2021.

She notes China is the second-largest global market for vitamins and dietary supplements, behind the US.

"However, the company has struggled to get across the regulatory environment, and changes in distribution channels has caused volatility," Quinn says.

Alongside the daigou channel, two key distribution methods for Blackmores are cross-border online sales and shopfront sales from supermarkets and pharmacies.

The lack of formal Chinese regulatory approval to sell from these physical storefronts continues to elude Blackmores, despite having been in the application process for more than five years.

"We understand this is a key point of focus for the new management team," Quinn says. She lifted the company's fair value estimate to $81 a share in October, following the appointment of CEO Alastair Symington and management's outline of a sustainable growth framework at its annual general meeting.

"We attribute recent disappointing performance to execution and regulatory issues, and not a changed regard for the Blackmores brand by the customer.

"Blackmores commands a price premium and its reputation for quality is its source of competitive advantage."

 

Glenn Freeman is Senior Editor at Morningstar Australia. This article is general information and does not consider the circumstances of any investor.


Try Morningstar Premium for free


 

RELATED ARTICLES

Why August company reporting season was poor

It’s getting hot in here

Six factors guide when to sell your winners

banner

Most viewed in recent weeks

How $200 billion is magically created

Australia is in a relatively good position to borrow $200 billion, with the RBA using printed money to buy bonds in the market. The long-term consequences are better than the alternative.

Howard Marks on 'Which way now?'

Howard Marks is the largest investor in the world in distressed securities. What does he think after checking the virus positives and negatives, and how much has he changed his mind in only a few days?

What are the possible economic effects of COVID-19 on the world economy?

In a widely-quoted scenario using estimated attack and fatality rates of coronavirus, about 0.07% of the population of the US dies. That's about 230,000 people, which the market is not ready for.

Note to Australia: be more French in the COVID-19 war

Andrew Baker is well-known as a superannuation consultant. Now working in the UK, he was caught in France with his family and is in lockdown. He worries Australian policy was too slow.

Welcome to Firstlinks Edition 351

The $130 billion wage stimulus is astounding in its generosity and scope. It's equivalent to the annual budgets for defence, education and health combined. A cafe owner told me a casual dishwasher who was paid $60 for two hours work a week now wants the $1,500 fortnightly payment. Shane Oliver exclusively explains where $200 billion will come from, and some longer-term consequences.    

  • 1 April 2020

Optimism among forecasts of the COVID-19 peak

This detailed analysis of infections, deaths, drugs and vaccines includes an optimistic scenario: perhaps US and Australian infection numbers will peak in early to mid-April with a decline after.

Latest Updates

Hamish Douglass on COVID-19: the three keys to the outlook

Hamish Douglass outlines three important issues in the outbreak of the coronavirus, and describes some consequences which may change businesses and consumers forever. We may never be the same.

Economy

Bill Gates: How to make up for lost time on COVID-19

Bill Gates warned the world in 2015 that we were not ready for the next inevitable pandemic, and we ignored him. The Washington Post has provided free access to his updated views.

Economy

How $200 billion is magically created

Australia is in a relatively good position to borrow $200 billion, with the RBA using printed money to buy bonds in the market. The long-term consequences are better than the alternative.

Investment strategies

Howard Marks on 'Which way now?'

Howard Marks is the largest investor in the world in distressed securities. What does he think after checking the virus positives and negatives, and how much has he changed his mind in only a few days?

Latest from Morningstar

Four stages of a typical bear market - but is this typical?

Bear markets caused by recession fears follow a pattern, but we have never seen anything like coronavirus. If financial stimulus and medicine prove ineffective, all bets are off. 

Economy

COVID-19 executes to a different playbook

The turning point in this crisis will be when the number of new COVID-19 cases starts to decrease. Until then, can we mitigate the damage to businesses and the economy so that we can snap back?

Investment strategies

Why technology stocks are good for the future

Over the long term, the technology sector has a vital role to make the essential transition to a more sustainable global economy and a cleaner planet. We highlight a few names with strong prospects.

SMSF strategies

Avoid complacency with your SMSF's investment strategy

Many trustees of SMSFs have become complacent about vague Investment Strategies, but fund auditors and regulators are paying far more attention. Ensuring your fund complies requires some simple changes.

Sponsors

Alliances

© 2020 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use.
Any general advice or class service prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, has been prepared by without reference to your objectives, financial situation or needs. Refer to our Financial Services Guide (FSG) for more information. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.